Abstract:Background: The transformation of airway smooth muscle cells (ASMCs) from a quiescent phenotype to a hypersecretory and hypercontractile phenotype is a defining feature of asthmatic airway remodeling. Fisetin, a flavonoid compound, possesses anti-inflammatory characteristics in asthma; yet, its impact on airway remodeling and ASMCs phenotype transition has not been investigated. Objectives: This research seeked to assess the impact of fisetin on ovalbumin (OVA) induced asthmatic airway remodeling and ASMCs phenotype transition, and clarify the mechanisms through network pharmacology predictions as well as in vivo and in vitro validation. Methods: First, a fisetin-asthma-ASMCs network was constructed to identify potential targets. Subsequently, cellular and animal studies were carried out to examine the inhibitory effects of fisetin on airway remodeling in asthmatic mice, and to detemine how fisetin impacts the phenotypic transition of ASMCs. Results: Network analysis indicated that fisetin might affect asthma via mediating the phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT) pathway. Intraperitoneal administration of fisetin in vivo reduced airway inflammation and remodeling, as shown by reduced inflammatory cells, decreased T helper type 2 (Th2) cytokine release, diminished collagen accumulation, mitigated airway smooth muscle thickening, and decreased expression of osteopontin (OPN), collagen-I and α-smooth muscle actin (α-SMA). Moreover, fisetin suppressed the PI3K/AKT pathway in asthmatic lung tissue. According to the in vitro data, fisetin downregulated the expression of the synthetic phenotypic proteins OPN and collagen-I, contractile protein α-SMA, and inhibited cellular migration, potentially through the PI3K/AKT pathway. Conclusion: These results suggest that fisetin inhibits airway remodeling in asthma by regulating ASMCs phenotypic shift, emphasizing that fisetin is a promising candidate for the treatment of airway smooth muscle remodeling.

FIZZ1 promotes airway remodeling through the PI3K/Akt signaling pathway in asthma.

FIZZ1 Promotes Airway Remodeling Through the PI3K/Akt Signaling Pathway in Asthma

FIZZ1 Promotes Airway Remodeling in Asthma Through the PTEN Signaling Pathway

FIZZ1 Plays a Crucial Role in Early Stage Airway Remodeling of OVA-Induced Asthma

FIZZ1 Induces Airway Epithelial to Mesenchymal Transition Leading to Early Airway Remodeling in Asthma

Found in Inflammatory Zone 1 Induces Angiogenesis in Murine Models of Asthma

Research Advancement on the Roles of FIZZ1 in Bronchial Asthma Pathogenesis

The in Vivo Fibrotic Role of FIZZ1 in Pulmonary Fibrosis.

Expression of FIZZ1 on lung tissue of cigarette smoking-induced COPD rats and its relationship with airway inflammation

FIZZ2/RELM-β Induction and Role in Pulmonary Fibrosis

Fisetin reduces ovalbumin-triggered airway remodeling by preventing phenotypic switching of airway smooth muscle cells

Effect of Cigarette Smoke Extraction on the Expression of Found in Inflammatory Zone 1 in Rat Lung Epithelial L2 Cells.

Phosphoinositide 3-Kinases Promotes Proliferation of Airway Smooth Muscle Cells in Asthmatic Rats

Inhibition of P21-Activated Kinase 1 Attenuates the Cardinal Features of Asthma Through Suppressing the Lymph Node Homing of Dendritic Cells.

Follistatin-Like 1 Induces the Activation of Type 2 Innate Lymphoid Cells to Promote Airway Inflammation in Asthma

Follistatin-related protein 1 in asthma: miR-200b-3p interactions affect airway remodeling and inflammation phenotype

YKL-40 mediates airway remodeling in asthma via activating FAK and MAPK signaling pathway.

Autophagy Plays a Role in FSTL1-induced Epithelial Mesenchymal Transition and Airway Remodeling in Asthma

IL-33 Promotes Airway Remodeling in a Mouse Model of Asthma Via ERK1/2 Signaling Pathway

Piezo Channels Modulate Human Lung Fibroblast Function

Focal Adhesion Kinase Regulates Collagen I–Induced Airway Smooth Muscle Phenotype Switching